Pharmacopsychiatry. 2012 Jan;45(1):37-9. doi: 10.1055/s-0031-1287776. Epub 2011 Oct 11.
Selective mutism is rare with a prevalence below 1% in the general population, but a higher prevalence in populations at risk (children with speech retardation, migration). Evidence for treatment strategies is hardly available. This case report provides information on the treatment of selective mutism in an 8-year-old girl with preexisting thalassaemia major. As medications she received penicillin prophylaxis (500000 IE/d) and deferasirox (Exjade; 20-25mg/kg/d), an iron chelator. The preexisting somatic disease and treatment complicated the treatment, as there are no data about pharmacological combination therapy. Psychotherapy in day treatment, supported by the use of the SSRI fluoxetine (10 mg), led to a decrease in the selective mutism score from 33 to 12 points, GAF improved by 21 points. Mean levels of fluoxetine plus norfluoxetine were 287.8 ng/ml without significant level fluctuations.
选择性缄默症在普通人群中的患病率低于 1%,属于罕见病,但在高危人群(有言语发育迟缓、移民等问题的儿童)中的患病率较高。目前几乎没有关于治疗策略的证据。本病例报告介绍了对一名患有严重地中海贫血症的 8 岁女孩选择性缄默症的治疗情况。她接受的药物治疗包括:青霉素预防治疗(50 万国际单位/天)和去铁酮(Exjade;20-25mg/kg/天),一种铁螯合剂。既往的躯体疾病和治疗使治疗变得复杂,因为目前尚无关于药物联合治疗的数据。在 SSRI 氟西汀(10mg)的支持下,日间治疗心理疗法使选择性缄默症评分从 33 分降至 12 分,GAF 提高了 21 分。氟西汀加去甲氟西汀的平均水平为 287.8ng/ml,没有明显的水平波动。